Fuad El Rassi

Fuad El Rassi

Auto-generated profile, based on publicly available information

Fuad El Rassi

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Haematologica
Verified
Journal Article
Closed access
PDF file
Ali TaherAli Taher
Ali Taher
FRF. El Rassi
F. El Rassi
HIH. Isma'EEl
H. Isma'EEl
SKS. Koussa
S. Koussa
AIA. Inati
A. Inati
MCMaria Domenica Cappellini
Maria Domenica Cappellini
Thalassemia intermedia is a highly diverse group of thalassemia syndromes associated with anemia and a range of specific complications, such as extramedullary hematopoiesis, leg ulcers, gallstones and a hypercoagulable state, which are uncommon in patients with thalassemia major.[1][1] The degree of

11 August 2009 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Ali TaherAli Taher
Ali Taher
Khaled MusallamKhaled Musallam
Khaled Musallam
FRFouad El Rassi
Fouad El Rassi
LDLorena Duca
Lorena Duca
AIAdlette Inati
Adlette Inati
MCMaria Domenica Cappellini
Maria Domenica Cappellini

12 January 2023 in Blood
Verified
Journal Article
Closed access
PDF file
CDCarlton D. Dampier
Carlton D. Dampier
MTMarilyn Jo Telen
Marilyn Jo Telen
TWTed Wun
Ted Wun
RBR. Clark Brown
R. Clark Brown
PDPayal Chandarana Desai
Payal Chandarana Desai
KHKathryn L. Hassell
Kathryn L. Hassell
The efficacy and safety of rivipansel, a predominantly E-selectin antagonist, were studied in a phase 3, randomized, controlled trial for vaso-occlusive crisis (VOC) requiring hospitalization (RESET). A total of 345 subjects (204 adults and 141 children) were randomized and 320 were treated (162 with rivipansel, 158 with placebo) with an IV loading dose, followed by up to 14 additional 12-hourly maintenance doses of rivipansel or placebo, in addition to standard care. Rivipansel was similarly administered during subsequent VOCs in the Open-label Extension (OLE) study. In the full analysis population, the median time to readiness for discharge (TTRFD), the primary end point, was not different between rivipansel and placebo (−5.7 hours, P = .79; hazard ratio, 0.97), nor were differences seen in secondary end points of time to discharge (TTD), time to discontinuation of IV opioids (TTDIVO), and cumulative IV opioid use. Mean soluble E-selectin decreased 61% from baseline after the loading dose in the rivipansel group, while remaining unchanged in the placebo group. In a post hoc analysis, early rivipansel treatment within 26.4 hours of VOC pain onset (earliest quartile of time from VOC onset to treatment) reduced median TTRFD by 56.3 hours, reduced median TTD by 41.5 hours, and reduced median TTDIVO by 50.5 hours, compared with placebo (all P < .05). A similar subgroup analysis comparing OLE early-treatment with early-treatment RESET placebo showed a reduction in TTD of 23.1 hours (P = .062) and in TTDIVO of 30.1 hours (P = .087). Timing of rivipansel administration after pain onset may be critical to achieving accelerated resolution of acute VOC. Trial Registration: Clinicaltrials.gov, NCT02187003 (RESET), NCT02433158 (OLE).

1 August 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZDZachariah DeFilipp
Zachariah DeFilipp
ALAmelia A. Langston
Amelia A. Langston
ZCZhengjia Chen
Zhengjia Chen
CZChao Zhang
Chao Zhang
MAMartha L. Arellano
Martha L. Arellano
HKHanna J. Khoury
Hanna J. Khoury

1 August 2008 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
HIHussain Isma'Eel
Hussain Isma'Eel
ACAbdul Hamid El Chafic
Abdul Hamid El Chafic
FRFuad El Rassi
Fuad El Rassi
AIAdlette Inati
Adlette Inati
SKSusan Koussa
Susan Koussa
Ali TaherAli Taher
Ali Taher

6 August 2013 in Cancer
Verified
Journal Article
Open access
PDF file
AAAna G. Antun
Ana G. Antun
SGShannon Gleason
Shannon Gleason
MAMartha Arellano
Martha Arellano
ALAmelia A. Langston
Amelia A. Langston
MMMorgan L. McLemore
Morgan L. McLemore
HKHanna J. Khoury
Hanna J. Khoury
BACKGROUND: Despite prophylactic platelet transfusions, bleeding remains a significant problem in thrombocytopenic patients.METHODS: The antifibrinolytic agent epsilon aminocaproic acid (EACA) was administered to 44 chronically (median duration, 273 days) and severely (platelet count, 8 × 109/L; range, 1 × 109/L‐ 19 × 109/L) thrombocytopenic patients with hematological malignancies. Prophylactic EACA at a dose of 1 g twice daily was orally administered for a median duration of 47 days (range, 7 days‐209 days) until the platelet count recovered to > 30; × 109/L. Platelets were only transfused if bleeding occurred.RESULTS: While receiving EACA, 59% of the patients did not bleed, 25% had 19 episodes of spontaneously resolving minor bleeding that did not require platelet transfusion, and 16% received a median of 4 platelet transfusions (range, 1 transfusion‐8 transfusions) for 1 major traumatic and 9 spontaneous grade 2 to grade 3 bleeding (based on the World Health Organization classification of idiopathic thrombocytopenic purpura). No EACA toxicities were noted, and venous thromboses were not observed.CONCLUSIONS: EACA is well tolerated and is associated with a low risk of major bleeding in patients with hematological malignancies who are experiencing chronic severe thrombocytopenia. Cancer 2013;119:3784–3787. © 2013 American Cancer Society.